ArticlePharmaceutics2022
Doxorubicin-Loaded Core-Shell UiO-66@SiO
Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 72 citations in OpenAlex.
- Use of the MOF NU-1000 as a Drug Delivery System for the Antineoplastic Drug Mitoxantrone.International journal of molecular sciences · 2026Article
- Endogenous and exogenous stimuli-driven intelligent nanocarriers: emerging strategies for the treatment of myocardial infarction.Journal of nanobiotechnology · 2026Review
- Synthesis and Pharmacokinetics of Nanosized NHDoklady. Biochemistry and biophysics · 2025Article
- Recent advances in zirconium-based catalysis and its applications in organic synthesis: a review.RSC advances · 2025Review
- Silver Nanoparticles Decorated UiO-66-NHPharmaceutics · 2025Article
- Metal-organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives.Journal of nanobiotechnology · 2025Review
- Cisplatin-loaded UiO-66-NHHeliyon · 2025Article
- Mesoporous silica nanoparticles--based functional platforms for breast cancer therapy: technological advancements.Frontiers in chemistry · 2025Review
- Metal-organic frameworks in drug delivery: engineering versatile platforms for therapeutic applications.RSC advances · 2024Review
- Preparation of UiO-66 loaded Letrozole nano-drug delivery system: enhanced anticancer and apoptosis activity.AMB Express · 2024Article
- An in-depth physicochemical investigation of drug-loaded core-shell UiO66 nanoMOFs.RSC advances · 2024Article
- Magnetic UiO-66-NHACS omega · 2023Article
- Metal-Organic Frameworks: Versatile Platforms for Biomedical Innovations.Materials (Basel, Switzerland) · 2023Review
- Article
- In Situ FTIR Spectroscopy for Scanning Accessible Active Sites in Defect-Engineered UiO-66.Nanomaterials (Basel, Switzerland) · 2023Article
- Utilization of Functionalized Metal-Organic Framework Nanoparticle as Targeted Drug Delivery System for Cancer Therapy.Pharmaceutics · 2023Review
- A pH-responsive bi-MIL-88B MOF coated with folic acid-conjugated chitosan as a promising nanocarrier for targeted drug delivery of 5-Fluorouracil.Frontiers in pharmacology · 2023Article
- New Nanosized Systems Doxorubicin-Amphiphilic Copolymers ofPharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
Beneficial features of biocompatible high-capacity UiO-66 nanoparticles, mesoporous SiO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.